Response rate to lenalidomide plus rituximab (R²) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

Diagnosis and management of follicular lymphoma: A comprehensive review

“…Subjects with benefit (at least stable disease) were then randomized to receive maintenance with lenalidomide (10 mg, d1‐21/28 days of cycle) plus rituximab or rituximab alone. Interim results of the postinduction data were presented recently and showed in FL arm with 186 patients a 1‐year rate for PFS of 68% (overall response rate 70%, CR 51%) . The study (NCT01996865) is ongoing.…”

“…Three-year PFS, percent TA B L E 3 FL is classified into the following 3 histologic grades tomography (FDG-PET) showed the potential to upstage approximately 10%-60% of patients with early stages to stages III and IV which subsequently change management of these patients. 17,18 Therefore, FDG-PET is a helpful tool to exclude advance stage prior potential curative treatment in early stages. Furthermore, it can help by determining the most suspected side for transformation to take biopsy.…”

“…Lenalidomide contributed to significantly better PFS (HR 0.46) than placebo. 49 18 The study (NCT01996865) is ongoing. The RELEVANCE trial which randomized untreated patients with FL to rituximab plus lenalidomide vs rituximab plus chemotherapy found lenalidomide arm as good as chemotherapy arm in terms of 3-year PFS.…”

Targeting CD20: teaching an old dog new tricks

“…The MAGNIFY study is a second randomized study in patients with relapsed and refractory FL, marginal zone lymphoma, and mantle cell lymphoma; it compares different durations of lenalidomide therapy and will help clarify the optimal length of lenalidomide therapy. 44 In the RELEVANCE trial, 1030 patients with treatment-naive follicular lymphoma were randomly assigned to either standard chemoimmunotherapy (investigator choice of bendamustine, rituximab [BR], R-CHOP, or rituximab, cyclophosphamide, vincristine, prednisone [R-CVP]) or the combination of lenalidomide and rituximab. Although the trial was designed to demonstrate superiority of the experimental regimen, overall response rates and progressionfree survival were highly similar between the 2 arms.…”

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

“…Results of the recently reported phase 3 RELEVANCE trial, evaluating R 2 versus R‐chemotherapy in previously untreated advanced FL patients, demonstrated similar efficacy in the two treatment arms, but found a greater frequency of grade 3/4 neutropenia was associated with R‐chemotherapy (Morschhauser et al , ). R 2 immunotherapy has also shown activity in marginal zone lymphoma (MZL), where the combination achieved an overall response rate (ORR) of up to 89% in phase 2 studies (Fowler et al , ; Sacchi et al , ) and is currently being evaluated in the phase 3 MAGNIFY study (Andorsky et al , ).…”